bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--Jun 2, 2025--
bluebird bio (NASDAQ: BLUE) ('bluebird'), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP ('SK Capital'). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer be publicly listed. Carlyle and SK Capital have provided significant primary capital to support and scale bluebird's commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
David Meek, who became Chief Executive Officer of bluebird at close, said, 'Today marks the beginning of a new era for bluebird as its go-forward financial backing and leadership team will better enable all stakeholders to realize the full potential of our revolutionary therapies. Historically, bluebird has excelled as a scientific innovator and should be very proud of the many achievements it has delivered to patients. Our vision is to further that legacy of scientific excellence while improving the commercial execution of our approved products to rapidly expand access to lifechanging gene therapies.'
'We are excited to back bluebird in partnership with SK Capital. We believe providing bluebird the necessary funding along with the new leadership team will help bluebird realize its full potential,' said Joe Bress, Carlyle Partner and Global Co-Head of Healthcare. Bali Muralidhar, Co-Managing Partner and Chief Investment Officer & COO of Abingworth, Carlyle's life sciences investment franchise, added, 'There is an incredible opportunity to bring bluebird's groundbreaking therapies to more patients in need, and we look forward to advancing bluebird in its mission.'
'SK Capital looks forward to partnering with David and his team as well as Carlyle to scale bluebird's pioneering gene therapies that can make a lifechanging difference for patients around the world,' said Aaron Davenport, Managing Director at SK Capital, adding, 'We believe our deep collective experience in manufacturing and commercializing therapies can help drive the next chapter of bluebird's growth.'
Incoming Team Bolsters Commercial Gene Therapy Experience
The company's momentum is reinforced by a deeply experienced management team, led by CEO David Meek. David brings more than 30 years of leadership in life sciences, including as CEO of Mirati Therapeutics and Ipsen. David is joined by Tom Klima as Chief Commercial & Operating Officer, Debasish Roychowdhury, M.D., as Chief Medical Officer, Wendy DiCicco as Chief Financial Officer, and Ellen Forest as Chief People Officer. Additional details are available at https://www.bluebirdbio.com/about-us/leadership.
From Scientific Breakthroughs to Delivery at Scale
With the transaction now closed, bluebird is prioritizing expanding its manufacturing infrastructure, streamlining the patient journey, supporting treatment centers, and strengthening its payer partnerships. The acquisition provides the strategic and financial backing needed to meet rising demand and drive commercial and operational excellence across the organization.
'bluebird has demonstrated what's possible through effective gene therapy,' David added. 'Now we will build the ecosystem to ensure every patient who needs these therapies can access them.'
About bluebird bio
bluebird bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. With more than a decade of scientific leadership in gene therapy and three FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, the company is committed to ensuring access, reliability, and patient-centered care. bluebird is headquartered in Somerville, Massachusetts.
About Carlyle
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and conducts its operations through three business segments: Global Private Equity, Global Credit and Carlyle AlpInvest. With $453 billion of assets under management as of March 31, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.
About SK Capital
SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, specialty materials, and ingredients sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2024. For more information, please visit www.skcapitalpartners.com.
Forward Looking Statement
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about bluebird's future goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond bluebird's control and could cause bluebird's future goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect bluebird bio's business, particularly those identified in the risk factors discussion in bluebird bio's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. These risks and uncertainties include, but are not limited to: the risk that the efficacy and safety results from bluebird's prior and ongoing clinical trials will not continue or be seen in the commercial context; the risk that there is not sufficient patient demand or payer reimbursement to support continued commercialization of bluebird's products; the risk of insertional oncogenic or other safety events associated with lentiviral vector, drug product, or myeloablation, including the risk of hematologic malignancy; and the risk that bluebird's products will not be successfully commercialized. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, bluebird bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250602288470/en/
CONTACT: Bluebird
Courtney O'Leary
+1 (978) 621-7347
[email protected]
Brittany Berliner
+1 (212) 813-4839
[email protected] Capital
Ben Dillon
+1 (646) 278-1353
[email protected]
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL GENETICS HEALTH
SOURCE: bluebird bio
Copyright Business Wire 2025.
PUB: 06/02/2025 08:34 AM/DISC: 06/02/2025 08:33 AM
http://www.businesswire.com/news/home/20250602288470/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Markets Slide to Flat on Jobs, Trade, Beige Book, Earnings
Wednesday, June 4, 2025Market activity this Hump Day was a little of this, a little of that. Pre-markets were lower on a weaker-than-expected private-sector payrolls report from ADP ADP, but most major market indexes spent most of the session in the green. This took a downward turn this afternoon, perhaps somewhat on a cooler Beige Book, but likely more a lack of enthusiasm to propel markets higher amid continuing trade is, after all, the self-imposed deadline for major deals to be announced with U.S. trading partners. Perhaps they're all waiting until this evening to spring the news, but currently there aren't any new trade deals. The Dow closed -0.18% while the S&P 500 was +0.01%. The Nasdaq, still kept somewhat aloft by the continuing AI trade, was +0.32%, and the small-cap Russell 2000 slipped -0.08%. The fourth of eight Beige Books this year from the Federal Reserve was released this afternoon for the month of May. Overall, it demonstrated a slight decline from the April 23rd report, with half of the 12 cities (regions) posting slightly negative economic growth: Boston, New York, Philadelphia, Minneapolis, Kansas City and San three cities that saw slight increases in economic activity were Richmond, VA, Atlanta and Chicago. Those flat cities from the prior report included Cleveland, St Louis and Dallas. All 12 districts saw an increase in economic and policy uncertainty, and showed manufacturing slowing as a result. Consumer spending throughout the regions were mixed, generally along economic growth lines. Earlier today, we saw the final print for both S&P Services PMI and ISM Services, both for May. S&P PMI came in higher than the flash headline — +53.7 versus +52.3 — and up strongly from the previous month's +50.8%. ISM Services dipped just below the 50% threshold to +49.9%, off the +52.1% flash number and the +51.6% reported the S&P PMI saw a stable business environment domestically (tempered somewhat by two-straight down months on foreign demand), ISM showed orders and inventories shrinking while prices continuing to rise — now at their highest levels since November 2022. The last sub-50% print on ISM Services was back in June of last year; S&P hasn't been sub-50 since January of '23. Youth-oriented discount retailer Five Below FIVE outperformed Q1 estimates on both top and bottom lines after today's close, with earnings of 86 cents per share surpassing the 83 cents in the Zacks consensus on $970.5 million in revenues. This improved over the $967.6 million analysts had been expecting. Comps were good at +7.1%, and Q2 comps guidance is set between +5-7%.The company has raised the lower end of their earnings guidance for the full year, but is still a few cents beneath our consensus. Also, Five Below announced that its COO will be stepping down for personal reasons, to be replaced by the current CFO, who used to have that job previously. Shares initially dipped on the news but at now back up +1.7% in late-day trading. As we see most Thursdays, Jobless Claims will hit the tape ahead of the opening bell tomorrow. These jobs numbers, finely parsed as they are into weekly sets, follow Tuesday's unexpected rise in JOLTS job openings for April to 7.4 million and this morning's lower-than-expected private-sector payrolls from ADP ADP. (Friday morning brings us the big Employment Situation report from the U.S. government.)Also tomorrow, we expect to see an update on the April U.S. trade deficit, expected to improve greatly to -$63.3 billion from -$140.5 billion in the prior month. Also, Q1 Productivity is expected to remain steady at -0.8% ahead of Thursday's opening bell. There will also be mid-day speeches given by Fed Governor Kugler and Philly Fed President Harker or comments about this article and/or author? Click here>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Automatic Data Processing, Inc. (ADP) : Free Stock Analysis Report Five Below, Inc. (FIVE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
an hour ago
How major US stock indexes fared Wednesday, 6/4/2025
U.S. stocks drifted through a quiet day of trading as Wall Street's momentum slowed following its big recent rally. The S&P 500 was essentially flat Wednesday and is within 2.8% of its all-time high. The Dow Jones Industrial Average slipped 0.2%, and the Nasdaq composite rose 0.3%. The action was stronger in the bond market, where Treasury yields tumbled following a pair of weaker-than-expected reports on the economy. The reports on the job market and output by U.S. services businesses raised expectations for coming cuts to interest rates by the Federal Reserve. Stock indexes rose across much of Europe and Asia. On Wednesday: The S&P 500 rose 0.44 points, or less than 0.1%, to 5,970.81. The Dow Jones Industrial Average fell 91.90 points, or 0.2%, to 42,427.74. The Nasdaq composite rose 61.53 points, or 0.3%, to 19,460.49. The Russell 2000 index of smaller companies fell 4.50 points, or 0.2%, to 2,098.48. For the week: The S&P 500 is up 59.12 points, or 1%. The Dow is up 157.67 points, or 0.4%. The Nasdaq is up 346.72 points, or 1.8%. The Russell 2000 is up 32.20 points, or 1.6%. For the year: The S&P 500 is up 89.18 points, or 1.5%. The Dow is down 116.48 points, or 0.3%. The Nasdaq is up 149.70 points, or 0.8%. The Russell 2000 is down 131.68 points, or 5.9%.
Yahoo
an hour ago
- Yahoo
Rivian Stock Dips Below $15: Should You Buy?
Rivian is struggling to grow deliveries but is improving cash burn. The company has a lot of cash and a partnership with Volkswagen. It is aiming to grow production, but is in a tough spot trying to increase customer demand. 10 stocks we like better than Rivian Automotive › Excitement around electric vehicles (EVs) has waned, at least in the United States. Tesla has lost its growth profile and is struggling to ship more units to customers. Chinese brands are taking increasing share in markets outside the United States. One EV upstart stuck in the mud is Rivian Automotive (NASDAQ: RIVN). The maker of high-end trucks and SUVs is experiencing falling deliveries to customers and is struggling to generate positive cash flow. The stock has fallen back below $15 as I write this, and is well off all-time highs from near its initial public offering. Does this make the stock a good buy-the-dip candidate today? The narrative around Rivian Automotive is sound. It is building premium EVs in America, tackling the high-end truck and SUV market, which has strong profit characteristics. It's got new factories under construction and more affordable vehicles coming down the line. And don't forget its EV delivery van product, which has a huge contract from Amazon -- an investor in the company -- as well as other buyers. These tailwinds are not showing up in the numbers today. Rivian expects to deliver 40,000 to 46,000 vehicles this year, compared to 51,579 in 2024. Demand seems to be waning for Rivian vehicles as it serves the high end of the EV space in the United States, which is quite niche. This is a problem that also happened to Tesla before it introduced its more affordable vehicles. Rivian hopes the same can occur with its upcoming R2 product, with plans for a starting price of $45,000. Encouragingly, Rivian has increased its profitability, bringing gross profit to a positive figure in the last two quarters. However, free cash flow is still deeply negative at a $1.86 billion burn over the last 12 months. The company needs more scale and better efficiency in order to build a sustainable business. It has made some progress in this regard, but still has a long slog ahead. Rivian's cash burn is ugly, but it has a lot of funding sources to help it keep building its production capacity over the next few years. There is still $7.2 billion in cash on the balance sheet, along with funding commitments from Volkswagen as part of a joint venture and a proposed $6.6 billion loan from the U.S. government. Volkswagen is a development and software partner for Rivian and plans to invest billions into the stock if Rivian can hit operational and gross profit milestones. Last quarter, Rivian saw a huge increase in its software and services revenue to $318 million compared to $88 million a year prior. A lot of this came from $167 million in revenue from the Volkswagen joint venture, which should help the company get closer to profitability. The segment had positive gross profit of $114 million last quarter. Overall, Rivian will need to get increased scale in its automotive business in order to generate positive free cash flow and become sustainable. It generated a slight gross profit for the automotive segment of $92 million last quarter, which is great progress compared to the ugly figures in years prior. Automotive gross margin was 10% last quarter. This figure will need to grow in the coming years to keep the company improving. If Rivian can return to growing deliveries with its upcoming cheaper models, there is a path to solid profit generation. Rivian generated $5 billion in revenue in 2024 even though its total deliveries were only around 50,000. If total deliveries can grow to 250,000 -- Tesla is close to 2 million, for reference -- I think $20 billion in revenue is possible. A 10% bottom-line net income margin that could occur once gross margin gets higher than today would equate to $2 billion in annual earnings. Given that, a current market cap of $16.6 billion looks mighty cheap. But how likely is the company to return to growth? I am not sure investors should be confident in this occurring. Competition is fierce in the EV space. You have Tesla, legacy competitors, Chinese players selling outside the United States, and other upstart EV brands trying to win customer loyalty. Rivian has a good product, but that does not necessarily mean it can compete and win in this market at scale, which it needs to do in order to succeed. It looks to me like Rivian's product demand is much lower than initially thought, which should keep investors away from the stock. If the company cannot scale customer demand, it will likely never generate a profit, making this a risky stock to buy today. Before you buy stock in Rivian Automotive, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rivian Automotive wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Brett Schafer has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Tesla. The Motley Fool recommends Volkswagen Ag. The Motley Fool has a disclosure policy. Rivian Stock Dips Below $15: Should You Buy? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
